Aeterna Zentaris Inc. stock is up 3.7% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 19 February’s closed higher than January.
Aeterna Zentaris Inc. engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR 1a. The company has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!